Gaucher disease: New developments in treatment and etiology

World Journal of Gastroenterology

Volumn 14, Issue 25, 2008, Pages 3968-3973

  Harmanci, Ozgur ^a   Bayraktar, Yusuf ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Enzyme replacement treatment; Gaucher disease; Gene therapy; Liver fibrosis; Substrate reduction treatment

Indexed keywords

ALGLUCERASE; CALCITRIOL; CHAPERONE; IMIGLUCERASE; LENTIVIRUS VECTOR; MIGLUSTAT; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; VITAMIN D; ALPHA GLUCOSIDASE; ENZYME INHIBITOR; GLUCOSYLCERAMIDASE;

ANEMIA; ASCITES; AUTOSOMAL RECESSIVE DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; DRUG HALF LIFE; ENZYME REPLACEMENT; GASTROINTESTINAL DISEASE; GAUCHER DISEASE; GENE MUTATION; HEPATOMEGALY; HUMAN; LIVER CIRRHOSIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SPLENOMEGALY; VIRAL GENE THERAPY; DRUG ANTAGONISM; ENZYMOLOGY; GENE THERAPY; METABOLISM; METHODOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ALPHA-GLUCOSIDASES; ENZYME INHIBITORS; GASTROINTESTINAL DISEASES; GAUCHER DISEASE; GENE THERAPY; GLUCOSYLCERAMIDASE; HUMANS; TREATMENT OUTCOME;

EID: 53449086596     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3968     Document Type: Review

References (55)

1. Scriver CR, Beaudet AL, Valle D, Sly WS. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill Pub, 2001: 3635-3668
2. Schnabel D, Schroder M, Sandhoff K. Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease. FEBS Lett 1991; 284: 57-69
3. Gurakan F, Terzioglu M, Kocak N, Yuce A, Ozen H, Ciliv G, Emre S. Analysis of three mutations in Turkish children with Gaucher disease. J Inherit Metab Dis 1999; 22: 947-948
4. Eto Y, Ida H. Clinical and molecular characteristics of Japanese Gaucher disease. Neurochem Res 1999; 24: 207-211
5. Wan L, Hsu CM, Tsai CH, Lee CC, Hwu WL, Tsai FJ. Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNcil and L444P mutations. Blood Cells Mol Dis 2006; 36: 422-425
6. Hodanova K, Hrebicek M, Cervenkova M, Mrazova L, Veprekova L, Zemen J. Analysis of the beta-glucocerebrosidase gene in Czech and Slovak Gaucher patients: mutation profile and description of six novel mutant alleles. Blood Cells Mol Dis 1999; 25: 287-298
7. Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, Tayebi N, Sidransky E. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 2000; 66: 1777-1786
8. Erdos M, Hodanova K, Tasko S, Palicz A, Stolnaja L, Dvorakova L, Hrebicek M, Marodi L. Genetic and clinical features of patients with Gaucher disease in Hungary. Blood Cells Mol Dis 2007; 39: 119-123
9. Alfonso P, Aznarez S, Giralt M, Pocovi M, Giraldo P. Mutation analysis and genotype/phenotype relationships of Gaucher disease patients in Spain. J Hum Genet 2007; 52: 391-396
10. Cox TM. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis 2001; 24 Suppl 2: 106-121; discussion 87-88
11. Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, Yatziv S. Cytokines in Gaucher's disease. Eur Cytokine Netw 1999; 10: 205-210
12. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005; 129: 178-188
13. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993; 268: 25803-25810
14. Owhashi M, Arita H, Hayai N. Identification of a novel eosinophil chemotactic cytokine (ECF-L) as a chitinase family protein. J Biol Chem 2000; 275: 1279-1286
15. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994; 93: 1288-1292
16. Guo Y, He W, Boer AM, Wevers RA, de Bruijn AM, Groener JE, Hollak CE, Aerts JM, Galjaard H, van Diggelen OP. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis 1995; 18: 717-722
17. Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, Mannens MM, Aerts JM. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 1998; 273: 25680-25685
18. Kurt I, Abasli D, Cihan M, Serdar MA, Olgun A, Saruhan E, Erbil MK. Chitotriosidase levels in healthy elderly subjects. Ann N Y Acad Sci 2007; 1100: 185-188
19. Brunner J, Scholl-Burgi S, Zimmerhackl LB. Chitotriosidase as a marker of disease activity in sarcoidosis. Rheumatol Int 2007; 27: 1171-1172
20. van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, Maas M, Hollak CE, Aerts JM, Rezaee F. Increased plasma macrophage inflammatory protein (MIP)-1alpha. and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 2007; 1772: 788-796
21. Moller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur J Haematol 2004; 72: 135-139
22. Benbassat J, Bassan H, Milwidsky H, Sacks M, Groen JJ. Constrictive pericarditis in Gaucher's disease. Am J Med 1968; 44: 647-652
23. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol 2007; 82: 697-701
24. Wenger DA, Clark C, Sattler M, Wharton C. Synthetic substrate beta-glucosidase activity in leukocytes: a reproducible method for the identification of patients and carriers of Gaucher's disease. Clin Genet 1978; 13: 145-153
25. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992; 71: 337-353
26. Xu R, Mistry P, McKenna G, Emre S, Schiano T, Bu-Ghanim M, Levi G, Fiel MI. Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature. Semin Liver Dis 2005; 25: 226-229
27. Erjavec Z, Hollak CE, de Vries EG. Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy. Ann Oncol 1999; 10: 243
28. Breiden-Langen CM, Buchsel R, Brambs HJ, Oehlert M, Matern S. [Coincidence of Gaucher disease with primary hepatocellular carcinoma] Leber Magen Darm 1991; 21: 126, 129-130
29. de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, Hollak CE. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006; 36: 53-58
30. Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005; 105: 4569-4572
31. Ben Harosh-Katz M, Patlas M, Hadas-Halpern I, Zimran A, Elstein D. Increased prevalence of cholelithiasis in Gaucher disease: association with splenectomy but not with gilbert syndrome. J Clin Gastroenterol 2004; 38: 586-589
32. Rosenbaum H, Sidransky E. Cholelithiasis in patients with Gaucher disease. Blood Cells Mol Dis 2002; 28: 21-27
33. Niederau C, Haussinger D. Gaucher's disease: a review for the internist and hepatologist. Hepatogastroenterology 2000; 47: 984-997
34. Lachmann RH, Wight DG, Lomas DJ, Fisher NC, Schofield JP, Elias E, Cox TM. Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM 2000; 93: 237-244
35. Neudorfer O, Hadas-Halpern I, Elstein D, Abrahamov A, Zimran A. Abdominal ultrasound findings mimicking hematological malignancies in a study of 218 Gaucher patients. Am J Hematol 1997; 55: 28-34
36. Lim AK, Vellodi A, McHugh K. Mesenteric mass in a young girl - an unusual site for Gaucher's disease. Pediatr Radiol 2002; 32: 674-676
37. Poll LW, Koch JA, vom Dahl S, Niederau C, Sarbia M, Haussinger D, Modder U. [Epigastric "Gaucher cell pseudotumor": image morphological and histological characteristics] Rofo 1998; 169: 669-672
38. Henderson JM, Gilinsky NH, Lee EY, Greenwood MF. Gaucher's disease complicated by bleeding esophageal varices and colonic infiltration by Gaucher cells. Am J Gastroenterol 1991; 86: 346-348
39. Jones DR, Hoffman J, Downie R, Haqqani M. Massive gastrointestinal haemorrhage associated with ileal lymphoid hyperplasia in Gaucher's disease. Postgrad Med J 1991; 67: 479-481
40. Brautbar A, Paz J, Hadas-Halpern I, Reinus C, Rosenmann E, Zimran A, Elstein D. Menetrier's disease presenting as an acute protein-losing gastroenteropathy in a 27-year-old man with Gaucher disease. Eur J Gastroenterol Hapatol 2005; 17: 670-681
41. Beutler E. Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab 2006; 88: 208-215
42. Bijsterbosch MK, Donker W, van de Bilt H, van Weely S, van Berkel TJ, Aerts JM. Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. Eur J Biochem 1996; 237: 344-349
43. Mistry PK, Wraight EP, Cox TM. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaudier's disease. Lancet 1996; 348: 1555-1559
44. Schiffmann R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, Barton NW, Rosenthal DI. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 2002, 28: 288-296
45. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122: 33-39
46. de Fost M, Aerts JM, Groener JE, Maas M, Akkerman EM, Wiersma MG, Hollak CE. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomdzed controlled trial. Haematologica 2007; 92: 215-221
47. Elbein AD. Glycosidase inhibitors: inhibitors of N-linked oligosaccharide processing. FASEB J 1991; 5: 3055-3063
48. Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 2005; 27: 1215-1227
49. Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaudier disease. J Inherit Metab Dis 2004; 27: 757-766
50. Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M. Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. Haematologica 2006; 91: 703-706
51. Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A, Giralt M, Heitner R, Hollak C, Hrebicek M, Lewis S, Mehta A, Pastores GM, Rolfs A, Miranda MC, Zimran A. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003; 26: 513-526
52. McEachern KA, Nietupski JB, Chuang WL, Armentano D, Johnson J, Hutto E, Grabowski GA, Cheng SH, Marshall J. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J Gene Med 2006; 8: 719-729
53. Kim EY, Hong YB, Lai Z, Kim HJ Cho YH, Brady RO, Jung SC. Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: implications for gene therapy of Gaudier disease. Biochem Biophys Res Commun 2004; 318: 381-390
54. Enquist IB, Nilsson E, Ooka A, Mansson JE, Olsson K, Ehinger M, Brady RO, Richter J, Karlsson S. Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci USA 2006; 103: 13819-13824
55. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 2002; 99: 15428-15433